Rakesh K. Jain, PhD
Trustee, HQH, HQL (since 2007), THQ (since 2014) and THW (since 2015); Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (2012-2018).
Thomas M. Kent, CPA
Trustee, HQH, HQL, THQ and THW (since 2017); Partner, PricewaterhouseCoopers LLP (1989-2013); Director, Principal Global Investors Trust Co. (since 2014); Director, Thayer Academy (2009-2018); Director, New England Canada Business Council (since 2017).
Elizabeth G. Nabel, MD
Trustee, HQH, HQL, THQ and THW (since 2018); President, Brigham Health and Professor of Medicine at Harvard Medical School (since 2010); Director, Medtronic (since 2014); Director, Moderna, Inc. (since 2015); Member of the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians and the American Society of Clinical Investigation; Fellow of the American Association for the Advancement of Science; serves on the boards of the Broad Institute, Ariadne Labs, and the Boys and Girls Club of Boston.
Daniel R. Omstead, PhD *
Trustee, HQH, HQL (since 2003), THQ (since 2014) and THW (since 2015); President, HQH, HQL (since 2001), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002); Director: Decipher Biosciences Inc. (since 2016); IlluminOss Medical, Inc. (since 2011); Joslin Diabetes Center (since 2016).
Oleg M. Pohotsky, MBA, JD
Trustee, HQH, HQL (since 2000) THQ (since 2014) and THW (since 2015); Consultant and Managing Partner, Right Bank Partners (since 2002); Adviser, Board Advisers, Kaufman & Co. LLC (since 2008); Director, Avangard Investment Holdings (since 2011); Director, The New America High Income Fund, Inc. (since 2013).
William S. Reardon, MBA
Trustee, HQH, HQL (since 2010), THQ (since 2014) and THW (since 2015); Independent Consultant (since 2002); Director, Idera Pharmaceuticals, Inc (since 2019).
Lucinda H. Stebbins, CPA, MBA
Trustee, HQH, HQL (since 2006), THQ (since 2014) and THW (since 2015); Independent Consultant, Deutsche Bank (2004-2015); Director, Solstice Home Care, Inc. (since 2014).
* Trustee considered to be an “interested person” within the meaning of the Investment Company Act of 1940, as amended, through a position or affiliation with Tekla Capital Management LLC.